NEU 0.00% $19.97 neuren pharmaceuticals limited

Ann: P2 trial shows significant improvements in Phelan-McDermid, page-207

  1. 5,791 Posts.
    lightbulb Created with Sketch. 735

    A quote from Larry Glass, CSO of Neuren: "Our goal is to get NNZ-2591 approved and make it available as quickly as humanly possible.



    On social media in Phelan chats
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.